AllAnalyst Report
logoMorningstarMay 06, 2021

Bio-Techne Corporation: Bio-Techne Reports Strong Growth and Improved Margin for Q3; Maintain $215 FVE

Symbols
TECH
Sector(s)
Healthcare
Rating
Current Price
$440.21
Fair Value
Economic Moat
Stewardship
Summary

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells a variety of antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers, and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

Aaron Degagne

Equity Analyst
Aaron DeGagne is an equity analyst, financial services, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and conducts general research on the global financial-services sector.Before joining Morningstar in 2017, DeGagne was an accounting intern for Campgroup and completed two lending-group internships with RBC Capital Markets.DeGagne holds a Bachelor of Business Administration in finance from the University of Notre Dame’s Mendoza College of Business.